Prademagene Zamikeracel

Summary

Prademagene Zamikeracel (CHEMBL4594312) is a phase-3 clinical-stage gene; indicated across 2 conditions including epidermolysis bullosa dystrophica.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• Indications: 2 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594312
Name	Prademagene Zamikeracel
Type	Gene
Max phase	3

Also known as: Eb-101, EB-101, Prademagen zamikeracel, Prademagene zamikeracel, PRADEMAGENE ZAMIKERACEL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
epidermolysis bullosa dystrophica	3	MONDO:0006543	MONDO:0009179

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04227106	PHASE3	COMPLETED	Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
NCT05708677	Not specified	ENROLLING_BY_INVITATION	A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).